Subscribe to RSS
DOI: 10.1055/a-1013-6382
Leg pain – dermatological causes
Article in several languages: deutsch | EnglishPublication History
26 July 2019
31 July 2019
Publication Date:
02 December 2019 (online)
Abstract
Introduction Vascular diseases are often suspected of being the cause of acute or chronic leg pain. However, the question also arises as to whether dermatological conditions may be associated with leg pain.
Methods Dermatological conditions are systematically presented with respect to concomitant or causal painfulness.
Results Pain is prominent with infections of the skin, while allergic or toxic contact dermatitis, pruritic diseases, and cutaneous autoimmune diseases are associated with pain.
Conclusions An underlying dermatological condition should be considered whenever there is leg pain of unknown origin. Pain may occur as a prodromal symptom of herpes zoster (shingles).
#
Introduction
Pain in the lower limbs is a common symptom. Suspecting a venous or at least a vascular origin of the pain, many patients seek an opinion from specialist in vascular diseases. Contrary to their expectations, a neuroskeletal cause in the lower back is often responsible [1]. Astonishingly, however, dermatological conditions are much less in focus than varicose veins when painful legs are the problem.
#
Methods
Starting with the symptom of non-vascular leg pain, this article presents skin diseases of varying aetiology. It focuses on dermatological diseases that more commonly affect the legs and describes the clinical picture of conditions frequently seen in dermatology or phlebology outpatient clinics.
#
Results
A wide variety of dermatological conditions may affect the lower limbs and be associated with pain. Pain may occur in numerous skin diseases ([ Table 1 ]), so the following addresses specific examples of typical clinical conditions.
#
Individual conditions
Soft tissue infections of the skin
Erysipelas
Erysipelas is a common infection of the skin. As a rule, the infection is due to β-haemolytic streptococci belonging to group A, more rarely to groups B, C, D or staphylococci. The organisms enter through small injuries (entry portals), penetrate the dermis, and spread through the lymphatic channels. The onset is typically acute with fever and shivering, while the characteristic sharply demarcated and very painful redness follows later. Erysipelas very commonly affects the legs, as the entry portal is often an area of tinea pedis (see [ Fig. 1 ]). Erysipelas requires systemic antibiotic therapy for at least 7–10 days [2]. Blister formation, bleeding, and necrosis may occur as complications. In rare cases, erysipelas may lead to sepsis.


Inadequate treatment of erysipelas or neglecting to treat the entry portal makes recurrence more likely. Recurrent erysipelas may lead to irreversible damage of the lymph channels and secondary lymphoedema may ensue [3]. This, in turn, may be the cause of further recurrences (see [ Fig. 2 ]). Further risk factors for recurrent erysipelas are anatomical considerations such as a pretibial site [4], concomitant venous insufficiency and/or lymphoedema [5], [6], and previous surgical procedures [7]. Furthermore, in such cases of chronic recurrent erysipelas, chronic pain in the affected limb is a very common symptom. Given the potential development of secondary lymphoedema, appropriate compression therapy should be included in the therapeutic approach to erysipelas.


#
Phlegmon
It is not easy to distinguish between erysipelas and a phlegmon. The course of a phlegmon involves deeper structures with purulent liquefaction and may result in extensive areas of necrosis or even sepsis (see [ Fig. 3 ]). There is often a mixed streptococcal and staphylococcal infection. The clinical picture is to be taken seriously, as involvement of the fascia (necrotising fasciitis) may have a fulminating course [8]. Besides the necessary surgical intervention, systemic antibiotic therapy is the mainstay of treatment.


#
Herpes zoster
Triggered by the reactivation of varicella-zoster virus in the posterior spinal ganglion, initial paraesthesias, such as burning or pain, occur before the typical distribution of blisters appears in the corresponding dermatome (see [ Fig. 4 ] and [ Fig. 5 ]). Relevant dermatomes in the leg are L3 to S1. Underlying malignant disease or immune deficiency should be ruled out in cases where several dermatomes are affected. Herpes zoster infection is characterised by intense pain that requires adequate systemic analgesia. The WHO analgesic ladder is to be recommended [9], [10].




#
#
Dermatitis
The term dermatitis is generally used to describe inflammatory diseases of the skin of varying aetiology. Extensive acute inflammation in particular may be intensely painful. Solar dermatitis (see [ Fig. 6 ]), toxic dermatitis (e. g. phytophotodermatitis), and allergic contact dermatitis (see [ Fig. 7 ]) can be mentioned in relation to painful cutaneous processes in the legs. The identification and future avoidance of the trigger are of key importance for these examples. Topical steroids are used in the first line of treatment.




#
Inflammation and pain as symptoms
Erythroderma
Erythroderma is understood to mean intense and usually widespread reddening of the skin due to inflammatory skin disease. It is a very severe form of disease and may be associated with pain, especially in the lower legs. The trigger may be acutely exacerbated psoriasis vulgaris [11], [12] or cutaneous lymphoma [13]. Erythroderma always needs a thorough diagnostic work-up, including dermatohistological and immunohistological examinations. Since erythroderma is not considered to be a clinical condition in its own right but rather a symptom or expression of a severe underlying disease, the various individual targeted treatments will not be considered in detail at this junction.
#
Urticaria
The characteristic symptom of acute and chronic urticaria is the presence of extremely itchy wheals that occur after the degranulation of mast cells lying in the subepidermal layers. Histamine and other inflammatory mediators are released. In some cases, headaches and joint pains or gastrointestinal symptoms occur together with the wheals. This can be explained by the activation and degranulation of extracutaneous mast cell populations [14]. The acute forms of urticaria are treated with antihistamines and, in some cases, with systemic steroids. Chronic urticaria requires a thorough diagnostic work-up in a specialist facility – basically the chronic spontaneous form has to be distinguished from the chronic inducible form. The treatment of chronic urticaria follows a stepwise approach, in which second generation H1-antihistaminienes are first increased up to four times the dose, omalizumab is then added if the initial treatment is not effective, and lastly ciclosporin is prescribed [15].
#
Prurigo/chronic pruritus
In many cases intense itching is experienced as pain, for example, the patient cannot distinguish whether it currently itches or hurts. The reason for this may be that the neurophysiology of itching and of pain have a lot in common [16], [17]. A typical skin condition that is characterised by itching and pain is nodular prurigo (prurigo nodularis). Nodular prurigo may also occur as a prodromal symptom of myeloproliferative diseases. It has been described in association with Hodgkin’s disease [18]. Prurigo usually responds very well to topical steroids.
Leg pain may occur in association with dermatological conditions. It is of significance in infections of the skin, as it may occur even before the appearance of the typical inflammatory lesions. In particular, it is a prodromal symptom of herpes zoster infection.
Leg pain may be present in non-infectious dermatological conditions as a symptom of an underlying inflammatory or autoimmune disease.
#
#
#
#
Interessenkonflikt / Conflict of interest
Der Autor gibt an, dass kein Interessenkonflikt besteht.
The authors declare that they have no conflict of interest.
-
Literatur / References
- 1 Stynes S, Konstantinou K, Dunn KM. Classification of patients with low back-related leg pain: a systematic review. BMC Musculoskelet Disord 2016; 17: 226
- 2 Jendoubi F, Rohde M, Prinz JC. Intracellular Streptococcal Uptake and Persistence: A Potential Cause of Erysipelas Recurrence. Front Med (Lausanne) 2019; 6: 6 Published 2019 Jan 29, doi:10.3389/fmed.2019.00006
- 3 McNamara DR, Tleyjeh IM, Berbari EF. et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167 (07) 709-715
- 4 Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Deutschen Dermatol Gesellschaft 2004; 2: 89-95
- 5 Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006; 155: 947-950
- 6 Bjornsdottir S, Gottfredsson M, Thorisdottir AS. et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005; 41: 1416-1422
- 7 Abrego MO, Saba JES, Halliburton C. et al. Fasciitis and Streptococcal Toxic-shock Syndrome: The Importance of Early Diagnosis and Surgical Management. J Orthop Case Rep 2018; 8 (05) 57-60 DOI: 10.13107/jocr.2250–0685.1212
- 8 Guerreiro de Moura CA, de Assis LH, Góes P. et al. A Case of Acute Generalized Pustular Psoriasis of von Zumbusch Triggered by Hypocalcemia. Case Rep Dermatol 2015; 7: 345-351 Published 2015 Dec 3 DOI: 10.1159/000442380
- 9 Klemke CD, Booken N, Weiss C. et al. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol 2015; 173: 93-105
- 10 Maintz L, Bieber T, Novak N. Die verschiedenen Gesichter der Histaminintoleranz: Konsequenzen für die Praxis. Dtsch Arztebl 2006; 103 (51/52) A 3477-3483
- 11 Schmelz M. Neurophysiologie des Juckreizes. Aktuelle Dermatologie 2013; 39: 218-222
- 12 Pereira 1 MP, Agelopoulos K, Köllner J. et al. Selective Nerve Fibre Activation in Patients with Chronic Generalized Pruritus May Indicate a Central Sensitization Mechanism. Acta Derm Venereol. 2019 [Epub ahead of print]
- 13 Dumont S, Péchère M ,, Toutous Trellu L. Chronische Prurigo: eine ungewöhnliche Manifestation des Hodgkin-Lymphoms. Karger Kompass Dermatol 2018; 6: 227-229
- 14 S2k Leitlinie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei ErwachsenenAWMF-Registernummer 082–006, aktualisiert 2. Januar 2019.
- 15 Maurer M, Zuberbier T, Siebenhaar F. et al. Chronische Urtikaria – Was bringt die neue Leitlinie?. J Deutsch Ges Dermatol 2018; 16: 585-595
- 16 Werner RN. et al. European consensus-based (S2k) guideline on the management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol 2017; 31 (01) 20-29
- 17 World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed.. Geneva: World Health Organization; 1996
- 18 Lemmenmeier E, Gaus B, Schmid P. et al. A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C. BMC Dermatol 2016; 16 (01) 5 Published 2016 May 26 DOI: 10.1186/s12895–016–0042–5
Korrespondenzadresse / Correspondence
-
Literatur / References
- 1 Stynes S, Konstantinou K, Dunn KM. Classification of patients with low back-related leg pain: a systematic review. BMC Musculoskelet Disord 2016; 17: 226
- 2 Jendoubi F, Rohde M, Prinz JC. Intracellular Streptococcal Uptake and Persistence: A Potential Cause of Erysipelas Recurrence. Front Med (Lausanne) 2019; 6: 6 Published 2019 Jan 29, doi:10.3389/fmed.2019.00006
- 3 McNamara DR, Tleyjeh IM, Berbari EF. et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167 (07) 709-715
- 4 Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Deutschen Dermatol Gesellschaft 2004; 2: 89-95
- 5 Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006; 155: 947-950
- 6 Bjornsdottir S, Gottfredsson M, Thorisdottir AS. et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005; 41: 1416-1422
- 7 Abrego MO, Saba JES, Halliburton C. et al. Fasciitis and Streptococcal Toxic-shock Syndrome: The Importance of Early Diagnosis and Surgical Management. J Orthop Case Rep 2018; 8 (05) 57-60 DOI: 10.13107/jocr.2250–0685.1212
- 8 Guerreiro de Moura CA, de Assis LH, Góes P. et al. A Case of Acute Generalized Pustular Psoriasis of von Zumbusch Triggered by Hypocalcemia. Case Rep Dermatol 2015; 7: 345-351 Published 2015 Dec 3 DOI: 10.1159/000442380
- 9 Klemke CD, Booken N, Weiss C. et al. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol 2015; 173: 93-105
- 10 Maintz L, Bieber T, Novak N. Die verschiedenen Gesichter der Histaminintoleranz: Konsequenzen für die Praxis. Dtsch Arztebl 2006; 103 (51/52) A 3477-3483
- 11 Schmelz M. Neurophysiologie des Juckreizes. Aktuelle Dermatologie 2013; 39: 218-222
- 12 Pereira 1 MP, Agelopoulos K, Köllner J. et al. Selective Nerve Fibre Activation in Patients with Chronic Generalized Pruritus May Indicate a Central Sensitization Mechanism. Acta Derm Venereol. 2019 [Epub ahead of print]
- 13 Dumont S, Péchère M ,, Toutous Trellu L. Chronische Prurigo: eine ungewöhnliche Manifestation des Hodgkin-Lymphoms. Karger Kompass Dermatol 2018; 6: 227-229
- 14 S2k Leitlinie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei ErwachsenenAWMF-Registernummer 082–006, aktualisiert 2. Januar 2019.
- 15 Maurer M, Zuberbier T, Siebenhaar F. et al. Chronische Urtikaria – Was bringt die neue Leitlinie?. J Deutsch Ges Dermatol 2018; 16: 585-595
- 16 Werner RN. et al. European consensus-based (S2k) guideline on the management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol 2017; 31 (01) 20-29
- 17 World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed.. Geneva: World Health Organization; 1996
- 18 Lemmenmeier E, Gaus B, Schmid P. et al. A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C. BMC Dermatol 2016; 16 (01) 5 Published 2016 May 26 DOI: 10.1186/s12895–016–0042–5



























